Key result
TMVr cuts 2-year death and heart failure hospitalizations in severe secondary mitral regurgitation.
Why the study?
Does transcatheter leaflet approximation (TMVr) reduce death and HF hospitalization in heart failure patients with 3+ or 4+ secondary mitral regurgitation?
RCT
Does transcatheter leaflet approximation (TMVr) reduce death and HF hospitalization in heart failure patients with 3+ or 4+ secondary mitral regurgitation?
Answers are grounded in this paper and cite their sources.
Strict application of COAPT echocardiographic criteria enables the translation of TMVr benefits (reduced death and HF hospitalization) to clinical practice for patients with secondary mitral regurgitation.
HF patients in the COAPT trial with 3+ or 4+ secondary mitral regurgitation, selected using strict echocardiographic criteria, benefitted from TMVr with reduced 2-year rates of death and HF hospitalization. Strict application of these echocardiographic criteria should enable the COAPT results to be translated to clinical practice. (Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation [The COAPT Trial] [COAPT]; NCT01626079).
No takes yet. Share an insight, caveat, or question.
Asch et al. (2019) conducted an RCT in Heart failure with secondary mitral regurgitation. Transcatheter mitral valve repair (TMVr) was evaluated on Death and heart failure hospitalization. Transcatheter mitral valve repair reduced 2-year rates of death and heart failure hospitalization in heart failure patients with 3+ or 4+ secondary mitral regurgitation.
Synapse has enriched 10 related papers. Consider them for comparative context: